Response to interleukin-6 receptor antagonists in patients with rheumatoid arthritis is independent of the number of prior used TNF inhibitors: A systematic review and metaanalysis-Reference-Cited by-同舟云学术

Response to interleukin-6 receptor antagonists in patients with rheumatoid arthritis is independent of the number of prior used TNF inhibitors: A systematic review and metaanalysis

Published:2021-01 Issue:1 Volume:88 Page:105112
ISSN:1297-319X
Container-title:Joint Bone Spine
language:en
Short-container-title:Joint Bone Spine

Author:

Narváez Javier^ORCID,Oton Teresa^ORCID,LLuch Judit,Mora-Limiñana Maribel,Nolla Joan Miquel,Loza Estíbaliz

Funder

Sociedad Española de Reumatología

Publisher

Elsevier BV

Subject

Rheumatology

Reference58 articles.

1. RoActemra (tocilizumab). European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra [2 November 2020, date last accessed].

2. Kevzara (sarilumab). European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara [2 November 2020, date last accessed].

3. Sarilumab: review of a second IL-6 receptor antagonist indicated for the treatment of rheumatoid arthritis;Boyce;Ann Pharmacother,2018

4. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicenter randomized placebo-controlled trial;Emery;Ann Rheum Dis,2008

5. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors;Fleischmann;Arthritis Rheumatol,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update;Journal of Clinical Medicine;2021-06-10